In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quigley earnings

This article was originally published in The Tan Sheet

Executive Summary

The Doylestown, Penn.-based firm reports a 58.1% increase in net sales for the third quarter to $15.3 mil. from $9.7 mil. in the year-ago period in an earnings announcement Oct. 27. The increase reflects a 85.1% rise in sales in the company's cold remedy segment. Sales for that division "continued to far outpace the growth in its category" for the third consecutive quarter, the firm said, noting that new product extensions of Cold-Eeze contributed to the growth. The segment's expansion also is a result of "the success of strategic advertising and marketing initiatives" and "a notable increase in consumer acceptance and expanded household penetration." Third-quarter net income was $3.0 mil. compared to $177,000 for the same period in 2004...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel